Messaging Strategies + Financial Incentive for Lung Cancer Screening Eligibility

Overseen By Hannah Toneff, MSW, MA

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Abramson Cancer Center at Penn Medicine

Disqualifiers: Lung cancer history, Completed LCS, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

6000 Participants Needed

Trial Summary

What is the purpose of this trial?

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Messaging Strategies + Financial Incentive for Lung Cancer Screening Eligibility?

Research shows that gain-framed messages, which highlight the benefits of quitting smoking, are more persuasive for smoking cessation than loss-framed messages. Additionally, financial incentives have potential in healthcare to encourage behavior change, suggesting that combining these strategies could effectively motivate individuals to participate in lung cancer screening. ^{1 2 3 4 5}

How does the treatment 'Messaging Strategies + Financial Incentive for Lung Cancer Screening Eligibility' differ from other treatments for lung cancer?

This treatment is unique because it combines messaging strategies with financial incentives to encourage people to get screened for lung cancer. Unlike traditional treatments that focus on medical interventions, this approach aims to increase screening rates by using persuasive communication and offering financial rewards to motivate individuals to participate in early detection efforts. ^{4 6 7 8 9}

Research Team

Katharine A Rendle, PhD,MSW,MPH

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for people aged 50-80 who've had a primary care visit at Penn Medicine between 2020-2025 and are eligible for lung cancer screening. It's not for those with a history of lung cancer, who've completed lung cancer screening at Penn Medicine, or don't want to be contacted for research.

Inclusion Criteria

Have completed at least one primary care visit at Penn Medicine in 2020-2025

I am between 50 and 80 years old.

Exclusion Criteria

Do not otherwise meet inclusion criteria

I have a documented history of lung cancer.

I do not wish to be contacted for research purposes.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Intervention

Participants receive different messaging strategies to assess response rates to a survey estimating lung cancer screening eligibility

7 days

Follow-up

Participants are monitored for survey completion rates and response to messaging

1-2 weeks

Treatment Details

Interventions

• Financial Incentive
• Framed Introductory Message A
• Framed Introductory Message B
• Framed Introductory Message C
• Framed Tobacco Use Message A
• Framed Tobacco Use Message B

Trial Overview The study is testing how different types of messages affect the response rates to a survey estimating eligibility for lung cancer screening. The goal is to find the most effective messaging strategy to encourage participation in future screenings.

Participant Groups

Group I: Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (CA) plus an incentive

Group II: Arm 8 (Introductory Message B + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (BB)

Group III: Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (BB) plus an incentive

Group IV: Arm 6 (Introductory Message B + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed messages (BA)

Group V: Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (BA) plus an incentive

Group VI: Arm 4 (Introductory Message A + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (AB)

Group VII: Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (AB) plus an incentive

Group VIII: Arm 2 (Introductory Message A + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed messages (AA)

Group IX: Arm 12 (Introductory Message C + Tobacco Use Message B) Experimental Treatment 2 Interventions

Participants will receive two framed messages (CB)

Group X: Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (CB) plus an incentive

Group XI: Arm 10 (Introductory Message C + Tobacco Use Message A) Experimental Treatment 2 Interventions

Participants will receive two framed message (CA)

Group XII: Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive) Experimental Treatment 3 Interventions

Participants will receive two framed messages (AA) plus an incentive

Who Is Running the Clinical Trial?

Abramson Cancer Center at Penn Medicine

Lead Sponsor

Trials

425

Recruited

464,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

National Institutes of Health (NIH)

Collaborator

Trials

2,896

Recruited

8,053,000+

References

1. United States pubmed.ncbi.nlm.nih.gov

Randomized trial: Quitline specialist training in gain-framed vs standard-care messages for smoking cessation. [2021]

2. England pubmed.ncbi.nlm.nih.gov

The identification of framed messages in the New York State Smokers' Quitline materials. [2021]

3. United States pubmed.ncbi.nlm.nih.gov

Principles to guide the development of population health incentives. [2021]

4. England pubmed.ncbi.nlm.nih.gov

Identification of gain- and loss-framed cancer screening messages that appeared in municipal newsletters in Japan. [2018]

5. United States pubmed.ncbi.nlm.nih.gov

How do perceptions about cessation outcomes moderate the effectiveness of a gain-framed smoking cessation telephone counseling intervention? [2021]

6. United States pubmed.ncbi.nlm.nih.gov

Promoting mammography appointment making. [2019]

7. United States pubmed.ncbi.nlm.nih.gov

Editorial: Financial Incentives to Improve Colorectal Cancer Screening: Does it Make Cents? [2021]

8. United States pubmed.ncbi.nlm.nih.gov

Financial Incentives for Promoting Colorectal Cancer Screening: A Randomized, Comparative Effectiveness Trial. [2018]

9. United States pubmed.ncbi.nlm.nih.gov

Message framing and parents' intentions to have their children vaccinated against HPV. [2018]